4.7 Article

The genetics of nodal marginal zone lymphoma

期刊

BLOOD
卷 128, 期 10, 页码 1362-1373

出版社

AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2016-02-696757

关键词

-

资金

  1. Fondazione Cariplo [2012-0689]
  2. Special Program Molecular Clinical Oncology [10007]
  3. Associazione Italiana per la Ricerca sul Cancro Foundation Milan, Italy [13470, iCARE 17860]
  4. Ministero della Salute, Rome, Italy [RF-2010-2307262, RF-2011-02349712]
  5. Ministero dell'Istruzione, dell'Universita e della Ricerca, Rome, Italy [RBFR12D1CB]
  6. Ateneo-San Paolo Program, Torino, Italy
  7. National Cancer Institute, National Institutes of Health [1 U54-CA193313-01]
  8. Swiss Cancer League, Bern, Switzerland [KFS-3746-08-2015]

向作者/读者索取更多资源

Nodal marginal zone lymphoma (NMZL) is a rare, indolent B-cell tumor that is distinguished from splenic marginal zone lymphoma (SMZL) by the different pattern of dissemination. NMZL still lacks distinct markers and remains orphan of specific cancer gene lesions. By combining whole-exome sequencing, targeted sequencing of tumor-related genes, whole-transcriptome sequencing, and high-resolution single nucleotide polymorphism array analysis, we aimed at disclosing the pathways that are molecularly deregulated in NMZL and we compare the molecular profile of NMZL with that of SMZL. These analyses identified a distinctive pattern of nonsilent somatic lesions in NMZL. In 35 NMZL patients, 41 genes were found recurrently affected in >= 3 (9%) cases, including highly prevalent molecular lesions of MLL2 (also known as KMT2D; 34%), PTPRD (20%), NOTCH2 (20%), and KLF2 (17%). Mutations of PTPRD, a receptor-type protein tyrosine phosphatase regulating cell growth, were enriched in NMZL across mature B-cell tumors, functionally caused the loss of the phosphatase activity of PTPRD, and were associated with cell-cycle transcriptional program deregulation and increased proliferation index in NMZL. Although NMZL shared with SMZL a common mutation profile, NMZL harbored PTPRD lesions that were otherwise absent in SMZL. Collectively, thesefindings provide new insights into the genetics of NMZL, identify PTPRDIesions as a novel marker for this lymphoma across mature B-cell tumors, and support the distinction of NMZL as an independent clinicopathologic entity within the current lymphoma classification.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据